Alzheimer’s Drugs Market Forecast Signals New Revenue Opportunities Through 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Alzheimer’s Drugs Market Size Forecast: How Large Could The Market Become By 2030?
The market for Alzheimer’s drugs has demonstrated robust expansion in recent years, with projections indicating a rise from $10.09 billion in 2025 to $10.99 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.9%. This growth in the historical period is largely driven by factors such as the growing elderly demographic, a higher incidence of Alzheimer’s disease, heightened awareness surrounding dementia care, the scarcity of effective therapies in earlier years, and progress in neuroscience research.
The market for Alzheimer’s drugs is projected to experience robust expansion in the coming years. By 2030, it is anticipated to reach a value of $15.4 billion, reflecting a compound annual growth rate (CAGR) of 8.8%. This projected growth in the forecast period is driven by developments in precision medicine, the incorporation of artificial intelligence into drug discovery, the enhancement of healthcare systems, governmental backing and financial support for dementia studies, and the emergence of digital health monitoring tools. Significant trends shaping the market during this period include the creation of tailored Alzheimer’s treatments, breakthroughs in neuroprotective medications, solutions for early detection and screening, therapies that combine multiple targets or agents, and systems designed to improve patient compliance and oversight.
Download A Free Sample Report For Comprehensive Market Insights:
#Alzheimer’s Drugs Market Growth Factors: Which Forces Are Supporting Market Expansion?
The growing incidence of Alzheimer’s disease is anticipated to drive expansion in the market for Alzheimer’s medications in the years ahead. This neurological disorder progressively worsens, leading to both brain shrinkage and cell death over time. Medicines developed for Alzheimer’s aim to address memory loss, cognitive difficulties, and challenges with reasoning, as well as obstacles encountered in daily activities. Such treatments can improve quality of life and support continued independence for those affected. According to a May 2024 report from the Alzheimer’s Association, a US-based nonprofit focused on care, support, and research for the condition, the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia grew from 6.5 million in 2022 to an estimated 6.9 million in 2024. Consequently, the rising frequency of Alzheimer’s disease is fueling growth within the Alzheimer’s drugs market.
Alzheimer’s Drugs Market Segmentation Trends And Revenue Drivers
The alzheimer’s drugs market covered in this report is segmented –
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Alzheimer’s Drugs Market Industry Trends: What Changes Are Reshaping Demand?
Major players operating in the Alzheimer’s drugs market are actively advancing novel treatments like amyloid plaque-targeting therapies in order to broaden therapeutic options and enhance clinical outcomes for patients. This specific therapeutic strategy aims to mitigate or impede the build-up of amyloid-beta plaques within the brain, a hallmark of Alzheimer’s pathology. A notable example occurred in June 2024, when Eli Lilly and Company, a pharmaceutical corporation based in the United States, obtained regulatory clearance from the Food and Drug Administration (FDA), an American federal agency responsible for safeguarding public health, for its drug Kisunla (donanemab-azbt). This medication stands as the first and only amyloid plaque-targeting therapy approved for early symptomatic Alzheimer’s disease. Its mechanism involves assisting the body in clearing surplus amyloid plaques from the brain, a process linked to cognitive deterioration among those affected by Alzheimer’s. Administered as an intravenous infusion once every four weeks, Kisunla follows an initial dosing schedule comprising three 700 mg doses, after which the dosage is increased to 1400 mg. The drug is indicated specifically for adults diagnosed with mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease, provided that the presence of amyloid pathology has been confirmed.
Alzheimer’s Drugs Market Industry Leaders: Which Organizations Are Driving Competition?
Major companies operating in the alzheimer’s drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.
Access The Complete Alzheimer’s Drugs Market Report:
Alzheimer’s Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North Americawas the largest region in the Alzheimer’s drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer’s drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
